Skin Manifestations Clinical Trial
Official title:
Split-Face Tolerability Comparison Between MetroGel® (Metronidazole Gel) 1% Versus Finacea® (Azelaic Acid) Gel 15% in Subjects With Healthy Skin
NCT number | NCT01139008 |
Other study ID # | US10159 |
Secondary ID | |
Status | Completed |
Phase | Phase 4 |
First received | |
Last updated | |
Start date | June 2010 |
Est. completion date | June 2010 |
Verified date | September 2012 |
Source | Galderma R&D |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The purpose of this study is to compare the tolerability of MetroGel® (metronidazole gel) 1% to Finacea® (azelaic acid) Gel 15% in subjects with healthy skin applied according to product labeling for three weeks.
Status | Completed |
Enrollment | 80 |
Est. completion date | June 2010 |
Est. primary completion date | June 2010 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Healthy male and female adults (ages 18 years or older) - Subjects with healthy skin as determined by the clinical grader Exclusion Criteria: - Subjects with a degree of skin pigmentation that interferes with the reading of skin reactions - Subjects with known allergy to one of the components of the study drugs (refer to the package inserts for MetroGel® 1% and Finacea® Gel 15%) - Subjects who have participated in another investigational drug or device research study within 30 days of enrollment - Subjects with a washout period for topical treatment on the treated area less than 1 week for corticosteroids and/or 4 weeks for retinoids - Subjects with a washout period for systemic treatment less than 1 week for medications that may increase photosensitivity and/or 4 weeks for corticosteroids and/or 6 months for retinoids - Subjects with current sunburn, eczema, atopic dermatitis, perioral dermatitis, rosacea, or other topical conditions on the area to be treated - Subjects who foresee unprotected and intense UV exposure during the study (mountain sports, UV radiation, sunbathing, etc.) |
Country | Name | City | State |
---|---|---|---|
United States | Thomas J. Stephens and Associates, Inc. | Carrollton | Texas |
Lead Sponsor | Collaborator |
---|---|
Galderma R&D |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Number of Participants Who Were a Success With Regard to Worst Post-baseline Tolerability Assessment Scores in Each Assessment (Erythema, Scaling, Dryness, Stinging/Burning) From Baseline to Week 3 | Number of participants who were a success with regard to worst post-baseline tolerability assessment scores in each of the tolerability assessments at any time point between baseline and week 3. Tolerability assessments (erythema, scaling, dryness, stinging/burning) are evaluated on a scale from 0 - 4 (0 = None, 1 = Mild, 2 = Moderate, 3 = Severe) with 0 being best and 4 being worst. Success was defined as a tolerability score of 0. | baseline to week 3 | |
Secondary | Number of Participants Who Were a Success With Regard to Worst-baseline Tolerability Assessment Scores in Each Assessment (Erythema, Scaling, Dryness, Stinging/Burning) on Day 22. | Number of participants who were a success with regard to worst-baseline tolerability assessment scores for each assessment (erythema, scaling, dryness, stinging/burning) on day 22. Tolerability assessments (erythema, scaling, dryness, stinging/burning) are evaluated on a scale from 0 - 4 (0 = None, 1 = Mild, 2 = Moderate, 3 = Severe) with 0 being best and 4 being worst. Success was defined as a tolerability score of 0 for each assessment. | Day 22 | |
Secondary | 6 Question Subject Preference Survey at Week 3 | Number of participants per response to each question of the Subject Preference Survey at week 3 | week 3 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05597254 -
Facial Skin Clinical and Microbial Profiling From Oral Probiotic Supplementation
|
N/A | |
Active, not recruiting |
NCT06140628 -
A 28-day Clinical Study on Facial Skin Rejuvenation
|
N/A | |
Completed |
NCT04154436 -
Effectiveness, Safety, and Cost Efficacy of Water (H2O) as a Substitute for Sodium Bicarbonate (NaHCO3) Plus Solution in Neutralization of Chemical Peeling Using 35% Glycolic Acid Solution
|
N/A | |
Withdrawn |
NCT02787356 -
Standard TDS Irritation Study: Trained Skin Grader vs. Digital Imaging
|
N/A | |
Completed |
NCT04449159 -
Efficacy of Vinh Wellness Collagen on Skin Health
|
N/A | |
Enrolling by invitation |
NCT06188338 -
A 56-day Clinical Study on Facial Skin Rejuvenation
|
N/A | |
Completed |
NCT01139047 -
Split-face Tolerability Comparison Between MetroGel® 1% vs Finacea® 15% in Subjects With Healthy Skin
|
Phase 4 | |
Completed |
NCT05094687 -
Cutaneous Manifestations of Coronavirus Disease 2019(COVID-19).
|
||
Recruiting |
NCT05235997 -
Placebo Controlled Efficacy Evaluation of the Hydrolyzed Collagen Peptide In Adult Females
|
N/A | |
Completed |
NCT01046396 -
Tolerability Comparison of Differin® Cream 0.1% Versus Differin® Lotion 0.1% in Subjects With Healthy Skin
|
Phase 1 | |
Completed |
NCT01046565 -
Tolerability Comparison Between Differin® Cream 0.1% Versus Differin® Lotion 0.1% in Subjects With Healthy Skin
|
Phase 1 | |
Completed |
NCT04701463 -
A Specialized Amino Acid Mixture on Body Composition and Skin State in Overweight and Obese Class I Postmenopausal Women
|
N/A | |
Completed |
NCT02422836 -
Tolerability and Efficacy of Anti-Aging Treatment Regimen in Subjects With Photodamage
|
N/A | |
Completed |
NCT04002856 -
Aesthetic Performance of "Profhilo®" Injective Intradermal Treatment for the Neck
|
N/A | |
Completed |
NCT03873896 -
The Skin Wrinkle Test: a Simple Clinical Test of Regional Block Success
|
N/A | |
Completed |
NCT03505684 -
Effect of Oral Collagen Tripeptide on Skin Moisture and Wrinkles in Adult Women
|
N/A | |
Active, not recruiting |
NCT06152718 -
New Regenerative Approach for Dermal Renovation (Karisma)
|
||
Recruiting |
NCT04344119 -
Assessment of Chilbains Occuring During Covid-19 Infection
|
||
Recruiting |
NCT06291415 -
The Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of HMPL-523 in Adult Subjects With Immune Thrombocytopenia (ITP)
|
Phase 1 | |
Completed |
NCT05872178 -
Omegia Softgel Clinical Research Program
|
N/A |